

# David Misdrahi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7729726/publications.pdf>

Version: 2024-02-01

83  
papers

1,932  
citations

218381

26  
h-index

315357

38  
g-index

92  
all docs

92  
docs citations

92  
times ranked

2521  
citing authors

#	ARTICLE	IF	CITATIONS
1	A National Network of Schizophrenia Expert Centres: an Innovative Tool to Bridge the Research-Practice Gap. <i>European Psychiatry</i> , 2015, 30, 728-735.	0.1	82
2	Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. <i>Schizophrenia Bulletin</i> , 2016, 42, 1290-1302.	2.3	82
3	Factors Predictive of Medication Nonadherence After Renal Transplantation. <i>Transplantation</i> , 2013, 95, 326-332.	0.5	68
4	The influence of therapeutic alliance and insight on medication adherence in schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 49-54.	0.7	64
5	Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients. <i>Scientific Reports</i> , 2016, 6, 38152.	1.6	64
6	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. <i>Schizophrenia Research</i> , 2015, 168, 388-394.	1.1	57
7	Pathways to care of first-admitted subjects with psychosis in South-Western France. <i>Psychological Medicine</i> , 2004, 34, 267-276.	2.7	51
8	Depression in schizophrenia: The influence of the different dimensions of insight. <i>Psychiatry Research</i> , 2014, 216, 12-16.	1.7	49
9	Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. <i>Schizophrenia Research</i> , 2017, 185, 173-181.	1.1	48
10	Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. <i>Psychiatry Research</i> , 2017, 257, 315-321.	1.7	48
11	Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model. <i>Journal of Affective Disorders</i> , 2007, 101, 35-41.	2.0	45
12	DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1). <i>European Psychiatry</i> , 2004, 19, 182-184.	0.1	44
13	Factors influencing compulsory admission in first-admitted subjects with psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2004, 39, 804-809.	1.6	41
14	Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. <i>Schizophrenia Research</i> , 2017, 182, 84-89.	1.1	41
15	Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 985-992.	1.8	39
16	Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database. <i>Brain and Behavior</i> , 2020, 10, e01495.	1.0	38
17	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. <i>Journal of Affective Disorders</i> , 2016, 191, 209-215.	2.0	37
18	Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. <i>British Journal of Psychiatry</i> , 2018, 213, 464-470.	1.7	35

#	ARTICLE	IF	CITATIONS
19	Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. <i>Schizophrenia Research</i> , 2015, 169, 255-261.	1.1	34
20	Prepartum chronic ultramild stress increases corticosterone and estradiol levels in gestating mice: Implications for postpartum depressive disorders. <i>Psychiatry Research</i> , 2005, 137, 123-130.	1.7	33
21	The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health. <i>Comprehensive Psychiatry</i> , 2009, 50, 181-185.	1.5	31
22	Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 332-339.	2.5	31
23	Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1130-e1136.	1.1	31
24	Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 541-553.	1.8	29
25	Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. <i>Schizophrenia Research</i> , 2018, 201, 373-380.	1.1	27
26	Machine learning for predicting psychotic relapse at 2â€ years in schizophrenia in the national FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 8-18.	2.5	27
27	Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. <i>Schizophrenia Research</i> , 2016, 175, 161-167.	1.1	26
28	Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. <i>European Neuropsychopharmacology</i> , 2018, 28, 24-36.	0.3	26
29	Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease. <i>Schizophrenia Research</i> , 2015, 161, 269-276.	1.1	23
30	Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 17-26.	1.8	23
31	Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	23
32	Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 449-457.	1.8	22
33	Pattern of health service utilization and predictors of readmission after a first admission for psychosis: a 2-year follow-up study. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 340-349.	2.2	21
34	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. <i>Psychopharmacology</i> , 2016, 233, 571-578.	1.5	21
35	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 567-577.	1.8	21
36	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	21

#	ARTICLE	IF	CITATIONS
37	Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Schizophrenia Bulletin Open, 2021, 2, sgab012.	0.9	20
38	Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 465-472.	1.8	18
39	Feasibility and validity of mobile cognitive testing in patients with substance use disorders and healthy controls. American Journal on Addictions, 2018, 27, 553-556.	1.3	18
40	Birth by cesarean section and schizophrenia: results from the multicenter FACE-SZ data-set. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 587-594.	1.8	17
41	Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMSÂ®): A six-month post-discharge prospective study. Schizophrenia Research, 2018, 193, 114-118.	1.1	16
42	Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). Cell Death and Disease, 2020, 11, 502.	2.7	16
43	Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality. Journal of Clinical Psychiatry, 2018, 79, .	1.1	16
44	Risk factors for increased duration of untreated psychosis. Results from the FACE-SZ dataset. Schizophrenia Research, 2018, 195, 529-533.	1.1	15
45	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. Journal of Psychiatric Research, 2017, 94, 62-69.	1.5	14
46	Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 62-68.	2.5	14
47	Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.. Psychiatry Research, 2018, 270, 104-110.	1.7	14
48	Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 599-610.	1.8	14
49	Mobile cognitive testing in patients with schizophrenia: A controlled study of feasibility and validity. Journal De ThÃ©rapie Comportementale Et Cognitive, 2018, 28, 204-213.	0.2	13
50	Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109654.	2.5	13
51	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 226-234.	2.5	12
52	Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109927.	2.5	11
53	A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France. Journal of Market Access & Health Policy, 2021, 9, 1885789.	0.8	11
54	Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.. Journal of Affective Disorders, 2020, 274, 617-623.	2.0	11

#	ARTICLE	IF	CITATIONS
55	Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone. <i>Patient Preference and Adherence</i> , 2015, 9, 1333.	0.8	11
56	Relationship between childhood trauma and level of insight in schizophrenia: A path-analysis in the national FACE-SZ dataset. <i>Schizophrenia Research</i> , 2019, 208, 90-96.	1.1	10
57	Brief interventions for improving adherence in schizophrenia: A pilot study using electronic medication event monitoring. <i>Psychiatry Research</i> , 2020, 285, 112780.	1.7	10
58	Impulsive aggressive obsessions following cerebellar strokes: a case study. <i>Journal of Neurology</i> , 2015, 262, 1775-1776.	1.8	9
59	Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort. <i>Schizophrenia Research</i> , 2018, 195, 357-365.	1.1	9
60	Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1196.	1.0	9
61	Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages. <i>European Psychiatry</i> , 2008, 23, 409-412.	0.1	7
62	Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort. <i>Psychiatry Research</i> , 2017, 254, 218-223.	1.7	7
63	A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort. <i>Schizophrenia Research</i> , 2019, 204, 38-45.	1.1	7
64	Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort. <i>Journal of Affective Disorders</i> , 2019, 245, 468-474.	2.0	7
65	Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 382-394.	2.3	7
66	Confirmation of a Two-Factor Solution to the Questionnaire of Cognitive and Affective Empathy in a French Population of Patients With Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 751.	1.3	6
67	Real-time cognitive performance and positive symptom expression in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 415-425.	1.8	6
68	Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: Findings from the FACE-SZ Cohort. <i>Psychiatry Research</i> , 2021, 303, 114044.	1.7	5
69	Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 525-536.	1.3	5
70	Psychiatric disability as mediator of the neurocognition-functioning link in schizophrenia spectrum disorders: SEM analysis using the Evaluation of Cognitive Processes involved in Disability in Schizophrenia (ECPDS) scale. <i>Schizophrenia Research</i> , 2018, 201, 196-203.	1.1	4
71	Outcome prediction with a social cognitive battery: a multicenter longitudinal study. <i>NPJ Schizophrenia</i> , 2021, 7, 30.	2.0	4
72	The EVACO Project: A new battery for assessing social cognition disorders and related psychiatric disability in schizophrenia. <i>European Psychiatry</i> , 2016, 33, S78-S78.	0.1	3

#	ARTICLE	IF	CITATIONS
73	Assessing metacognitive and help-seeking strategies in schizophrenia: design and psychometric validation of the Versailles Metacognitive Strategies Evaluation Questionnaire. <i>Clinical Rehabilitation</i> , 2020, 34, 263-275.	1.0	3
74	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110275.	2.5	3
75	Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110335.	2.5	3
76	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 703-714.	1.3	2
77	Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 1379-1384.	1.8	2
78	Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 22, 100436.	1.3	2
79	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. <i>Cognitive Neuropsychiatry</i> , 2022, 27, 49-68.	0.7	2
80	Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 1.	1.8	2
81	Insight et schizophrénie : quels rôles dans le risque suicidaire?. <i>Annales Medico-Psychologiques</i> , 2011, 169, 426-428.	0.2	1
82	Trastornos mentales del DSM-IV y complicaciones neurológicas en niños y adolescentes con infección por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1). <i>European Psychiatry (Ed Española)</i> , 2004, 11, 387-390.	0.0	0
83	Exploration de l'observance dans la schizophrénie : de la recherche aux implications cliniques ?. <i>French Journal of Psychiatry</i> , 2018, 1, S97-S98.	0.1	0